Mechanical Circulatory Support in Complex Anatomies and Severe Deterioration of Left Ventricular Function

Severe coronary artery disease (CAD) frequently causes left ventricular function deterioration, and is often treated with myocardial revascularization surgery (CABG), especially when ejection fraction is ≤35%. 

Asistencia ventricular en anatomías complejas y deterioro severo de la función ventricular izquierda

However, CABG is not always a viable choice, because of multiple comorbidities, which makes percutaneous coronary intervention (PCI) a valid alternative. In this scenario, chronic total occlusion (CTO) is frequent, which increases the risk of complications and ischemia during procedure, be it anterograde or retrograde, compromising also donated vessels. Even though still controversial, in these cases, using mechanical circulatory support devices can be the right strategy. 

27 severe CAD patients were analyzed; there was at least one CTO and severe left ventricular dysfunction. 

Primary end point was MACE, a composite of cardiovascular death, MI and target lesion revascularization (TLR) at 90 days.  

Mean patient age was 63, and 25 were men. Mean EuroSCORE was 5.07. As regards comorbidities, 11 were diabetic, 19 hypertensive, 19 had cardiac failure, 7 prior PCI, 4 prior CABG, 2 prior stroke, 3 had atrial fibrillation, 9 had peripheral vascular disease and 7 had kidney function deterioration. Mean ejection fraction was 23 ± 7%. 

Read also: Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation.

SYNTAX score was 37. In total, 38 CTO were treated; 14 patients presented three-vessel disease, and 11 two-vessel. The most frequent CTO was to the right coronary, followed by the anterior descending (AD) and, in lower proportion, the circumflex (CX). Mean J-CTO score was 2, with estimated MACE risk 2.5%. 

Impella Access site was transfemoral for 23 patients, 3 were transaxillary procedures and 1 transcarotid. Complete revascularization was achieved in 15 patients (56%).

At hospital level, one patients died of pericardial effusion, another had an MI and 3 had vascular complications.

Read also: TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

At 90 days, the primary outcome was seen in 3 patients: two deaths and 1 TLR. However, 22 patients experienced significant improvement of angina and dyspnea. Also there was a significant increase in ejection fraction, up to 33%, with a relevant reduction of systolic and diastolic volume. 

Conclusion

In high risk patients with severe ventricular function deterioration and complex anatomy, including CTO, PCI with mechanical circulatory support with Impella was associated with a favorable evolution in terms of safety and efficacy at short term. 

Original Title: Mechanical Circulatory Support With Impella in High‐Risk Patients With Chronic Total Occlusion and Complex Multivessel Disease. 

Reference: Ignacio Gallo, et al. Catheterization and Cardiovascular Interventions, 2025; 105:883–890 883 of 980 https://doi.org/10.1002/ccd.3139.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

Más artículos de este Autor

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas SOLACIspot_img

Artículos recientes

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....